When Multinational Pharmaceutical Companies Enter Nine Countries In Boao, The Passenger Flow Changes.

In December 7th, Johnson announced the launch of the Johnson Boao innovation chain. At the same time, many multinational pharmaceutical companies also entered the leading area. After nine countries, the Boao medical pilot zone (hereinafter referred to as the "Boao first district") welcomed the turn of the passenger flow.

Boao's leading area has always been a policy darling. In September 2019, the policy "gift package" came again, and the four departments such as the national development and Reform Commission issued the implementation plan to support the construction of the leading area. In accordance with the upgraded version of the "nine countries", imported drugs can not only be used in the leading areas, but also patients can take the imported medicines of "reasonable use of their own quantity" away from the leading areas. It has a positive impact on accelerating the examination and approval and shortening the return of overseas medical treatment.

With the advance of the real world research policy in the leading area of Boao, the major multinational pharmaceutical companies have entered the Bureau. RealWorldStudy (RWS) refers to mining information from multiple datasets other than traditional evidence-based clinical research, and adopting a non randomized, open, placebo-free study. RWS evidence can complement each other provided by traditional clinical trials to form a complete and rigorous chain of evidence.

In addition to Johnson, in December 2nd, Mercedes also exchanged with the Hainan provincial drug administration and Boao Le Cheng administration. The two sides exchanged views on the first trial of new drug in Mercedes, the application of unapproved indications, the feasibility of landing the patient assistance program, and the research and application of real world data.

Multinational pharmaceutical enterprises drainage

Multinational pharmaceutical companies continue to be active in the antecedent area. In October this year, Johnson medical and Lok Cheng International Medical Tourism Pioneer Area launched the joint observation research project of the national Department of orthopedics and sports rehabilitation clinical medicine research center. It is hoped that the joint clinical research team of China should be established to carry out joint surgery real world research, accelerate the introduction of new technologies and develop new technologies. Johnson said it will also promote the establishment of other departments in the future.

"Multinational pharmaceutical companies are willing to cooperate with us because they have the opportunity of real world research, which can help them quickly enter the Chinese market. We used to cooperate with multinational pharmaceutical companies to find them according to the needs of patients. This cooperation is only a simple distributor relationship, and the amount of drugs used in the leading area is very small, so they have little interest in this kind of cooperation. Now, the cooperation between multinational pharmaceutical companies and the leading area has become a cooperation that concerns future development, so they will put a lot of power into it and speed up the layout in the leading area. Gu Gang, director of the Hainan Boao Le Cheng International Medical Tourism front district administration, said in an interview with the twenty-first Century economic news reporter.

In September this year, the national development and Reform Commission and other four ministries jointly issued the "implementation plan for supporting the construction of the first district of Boao Le Cheng International Medical Tourism". It is clear that the clinical data of medicines and medical devices that are not registered in China and imported urgently need to be translated into real world evidence for registration and approval in China and shorten the time for products to be listed. In accordance with the implementation plan, by 2025, Boao's leading areas will achieve "three synchronization" with the international advanced level in terms of medical technology, equipment and medicines.

At present, Boao's Pioneer Area has identified four varieties of three enterprises as the first batch of pilot projects in October 17th, including the drainage tube for the treatment of glaucoma by eljian, Collier's NG voice processor, Johnson femtosecond product for cataract treatment, and Medtronic's treatment for moderate and deep varicose veins.

Jia Ning, director of the Hainan provincial drug administration, has revealed that a product has been approved before the first half of next year. Next, the second batch of product exchange meetings will be held in early December to identify the second batch of products that will conduct real world data research.

Jia Ning also said that for the study of real world data, Boao Le Cheng first used several varieties as a pilot project to ensure that the data can be traced to the source and meet the needs of examination and approval by means of database. The next step will be to establish a special platform for real world data research. First, we can greatly shorten the time for innovative weapons to enter the country; the two is to greatly reduce the cost of entering China; the three is to allow more patients to enjoy better treatment in China; and finally, to consolidate the leading position of Boao to become the gateway of the world's advanced weapons and equipment to China.

"If China wants to become a leader in the medical industry innovation, the speed of listing must be the first in the world. The pharmaceutical companies will take the initiative to put R & D personnel and resources into the Chinese market." Wang Jinhe, general manager of cardiovascular and professional solutions division of Johnson (Shanghai) Medical Devices Co., Ltd.

Never ending mode

Under the policy stimulus, the biggest weakness of Boao's leading area lies in the scarcity of former patients' resources. Gu Gang told reporters that despite the shortage of patients, the situation has improved since September.

In the past, the first area of medical treatment in Boao was mostly airport mode. Experts and patients with need came to Boao for treatment. Gu Gang told the twenty-first Century economic news reporter that the future mode will be developed by strengthening the facilities construction, including attracting public tertiary hospitals, and developing the airport model and never ending mode.

"The policy of Boao Le Cheng in real world research has made great innovations. If the medical tourism is done more, including payment, the whole platform can be built better." Zhou Mintao, general manager of Johnson healthcare Co., Ltd.

"There are few comprehensive reasons for patients, and the policy of Boao's leading area is landing. At present, only a year and a half has not officially begun. We fumbled from the patient's medication. For example, before the patient's medication, it takes 27 days to 6 months, and now only 3 to 7 days, cochlear patients also grow very fast. We hope that through the long-term exhibition, the pharmaceutical companies will provide us with the list of products, and we should look for patients and drain patients to overseas hospitals. Gu Gang said.